You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel Combinations of Natural Product Compounds for Treatment of Alzheimer Disease and Related Dementias
SBC: Path Biotech, LLC Topic: NIAPROJECT SUMMARY/ABSTRACT In response to National Institute on Aging's (NIA) strategic plan and PAS-19-317, we propose novel therapeuticsto treat Alzheimer disease and related dementias (ADRDs). We have developed novel combinations of three natural product compounds, which modulate complementary pathways in multiple types of CNS cells (i.e., neurons, microglia) associated with AD pathology. These c ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
ICU-CARE: An interactive mobile app to enhance the efficiency of daily informal caregiving in the intensive care unit
SBC: SILICON CURES LLC Topic: NINRPROJECT SUMMARY Actively involving informal caregivers in direct patient care at the bedside in the intensive care unit (ICU) has the potential to improve patient, informal caregiver, and health care system outcomes. Practice guidelines call for the liberal inclusion of informal caregivers as active partners in ICU care, but there is a critical, unmet need to develop tools that effectively operati ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Identification of Mixed NOP/mu partial agonists as lead compounds for treatment ofmethamphetamine use disorder
SBC: PHOENIX PHARMALABS, INC. Topic: NIDAAbstract Currently, clinically used drug abuse medications exist for treatment of addiction to opiates, alcohol, and nicotine, but not psychostimulants, such as methamphetamine (METH). Compounds that co-activate both nociceptin opioid peptide (NOP) and mu receptors have potential for treatment of drug abuse. In particular, buprenorphine, a partial mu agonist/kappa antagonist, which also acts as a ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Glycan biomarker panels in liquid biopsies for predicting treatment response in lupus nephritis
SBC: GLYCOPATH INC Topic: 400Lupus nephritis (LN), an immune complex-mediated glomerulonephritis, affects up to two-thirds of patients with systemic lupus erythematosus. Despite standard treatment protocols, progression of the most aggressive forms of LN (class III and IV) to end-stage renal failure remains high. Thus, there is a need for biomarkers of therapeutic response that would allow physicians to make better-informed t ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel sensor for the real-time measurement of mitral coaptation force
SBC: MitralPint Inc. Topic: NHLBIProject Summary The proposed project will develop a breakthrough endovascular sensor technology to allow for real-time quantification of the mitral coaptation force (MCF) of the mitral valve during both open and percutaneous mitral valve repair (MVR). Mitral regurgitation (MR) is the most common heart valve disorder in the U.S. population, with over 2 million individuals affected. Current methods ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing natural compound emodin as a therapy for alcoholic cardiomyopathy
SBC: AcePre, LLC Topic: NIAAAProject Summary: Alcoholic Cardiomyopathy (ACM) is the most prevalent form of ethanol-induced heart damage. Alcohol dose-dependently induces ACM, characterized by progressive reduction in myocardial contractility and ventricular dilatation, culminating in heart failure. At the cellular level, chronic alcohol consumption results in cardiomyocyte death, cardiac inflammation, and cardiac fibrosis. Th ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development
SBC: FIBROTHERAPEUTICS INC Topic: NHLBIAbstract Our long-term objective is to fill the unmet need for treatments for heart failure (HF). Caveolin-1 is a promising therapeutic target in fibrotic diseases. The profibrotic effects of caveolin-1 deficiency in cells and in mouse models is suppressed by a peptide equivalent to its active site (caveolin-1 scaffolding domain, CSD). We have shown the beneficial effects of CSD in two independent ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A novel platform for synthetic generation and statistical obfuscation of tabular clinical data, simulated images, and machine-generated text
SBC: GRAYRAIN, LLC Topic: NCATSPROJECT SUMMARY Data is a critical and highly valuable commodity, driving meaningful change in our society, especially when it pertains to patient care and biomedical research. Currently, institutions pay inordinate sums to increase, regain, and complement their data panels. As an extra burden, data legislation and privacy protection regulations introduce barriers to forming effective partnerships ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis
SBC: FibroBiologics, LLC Topic: NHLBIIdiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a median survival of only 3 - 5 years from diagnosis. Although two FDA-approved drugs, pirfenidone and nintedanib, may slow the rate of decline of lung function in some IPF patients, neither drug significantly alters the course of this lethal disease. There is a great need for new drugs with greater efficacy and le ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Structure-based computational engineering of saCas9 PAM requirement
SBC: ATGC Inc. Topic: 400ABSTRACT SaCas9 is a major gene editing nuclease that is preferred for in vivo applications thanks to its relatively smaller size compared to that of spCas9. One limiting factor for the use of saCas9 is its strict PAM requirement of NNGRRT. In addition, there are limited efforts to reduce saCas9’s off-target editing rates. In Aim 1, we propose a computational approach to relax saCas9’s PAM req ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health